Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATP8A2
REST API REST API
Homo sapiens
ATP8A2 is differentially expressed in 222 experiments: 168 organism parts: amygdala, cerebellum, ... (166 more);, 130 disease states: normal, chronic lymphocytic leukemia, ... (128 more);, 81 cell types 233 cell lines 23 compound treatments and 79 other conditions.
Synonyms ML-1, ATPIB
Orthologs Atp8a2 (Mus musculus)   LOC691889 (Rattus norvegicus)   ENSCING00000015145 (Ciona intestinalis)   ATP8A2 (Gallus gallus)   DRS2 (Saccharomyces cerevisiae)   ENSCING00000005920 (Ciona intestinalis)   ATP8A2 (Danio rerio)   ATP8A2 (Bos taurus)   CG42321 (Drosophila melanogaster)   atp8a2 (Xenopus laevis)   ENSCAFG00000007007 (Canis familiaris)   ENSCAFG00000025477 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism, negative regulation of cell proliferation, membrane, metal ion binding, cation transport, phospholipid transport, phospholipid-translocating ATPase activity, ATP binding, magnesium ion binding, hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances, nucleotide binding, ATP biosynthetic process, integral to membrane, hydrolase activity
InterPro Term ATPase_P-typ_Plipid-transl, ATPase_P-typ_ion-transptr, ATPase_P-typ_ATPase-assoc-dom
UniProt Accession Q9NTI2, B1ALJ8, F5GZN5, B7Z880, F8W9B3
Search EB-eye ENSG00000132932
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (30 experiments)

Factor Value U/D Experiments
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
MOLT4
2
E-MTAB-62, E-MTAB-37
BT474
1
2
E-MEXP-440, E-MTAB-37, E-MTAB-62
A549
3
1
E-GEOD-6013
DU4475
1
E-MTAB-37
227 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, ... (41 experiments)

Factor Value U/D Experiments
endothelial cell
1
2
E-GEOD-3920, E-GEOD-3998, E-GEOD-96
keratinocyte
1
E-GEOD-3204
adipocyte
1
E-AFMX-5
T-cell
1
E-GEOD-10820
germ cell
1
E-MTAB-25
BDCA4+ dentritic cell
1
E-TABM-145
75 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1615, E-GEOD-6872, E-GEOD-15960, E-GEOD-2466, ... (45 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MTAB-62, E-MEXP-1327, E-MEXP-2034
T-cell acute lymphoblastic leukemia
2
E-MTAB-37, E-GEOD-1577
glioblastoma
2
E-GEOD-4290, E-MEXP-567
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
monoclonal gammopathy of unknown significance
1
E-MTAB-62
muscle invasive carcinoma
1
E-GEOD-3167
124 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-15205, E-GEOD-412, E-GEOD-5824, ... (10 experiments)

Factor Value U/D Experiments
vanadium pentoxide
1
E-GEOD-5339
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
unknown
1
E-GEOD-7307
estradiol
1
E-GEOD-20081
glucose
1
E-MEXP-941
heregulin
1
E-GEOD-6462
17 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847 ... (5 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20559, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-19330, E-TABM-666, E-GEOD-19519, ... (19 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-3494

Processing time: 0.448 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM